Sees FY25 LINZESS U.S. sales $800M-$850M. Sees FY25 adjusted EBITDA greater than $85M. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks >> Read More on IRWD: Ironwood price target lowered to $8 from $10 at Craig-Hallum Ozempic, Xtandi among next 15 drugs selected for U.S. price talks Ironwood jumps after FDA rejects Zealand short bowel syndrome drug application Beam Therapeutics appoints Sravan Emany as CFO Disclaimer & DisclosureReport an Issue
